Abivax (NASDAQ:ABVX) Sees Unusually-High Trading Volume After Analyst Upgrade

Abivax SA Sponsored ADR (NASDAQ:ABVX) shares saw unusually-high trading volume on Monday after Morgan Stanley raised their price target on the stock from $101.00 to $145.00. Morgan Stanley currently has an overweight rating on the stock. Approximately 2,646,946 shares traded hands during trading, an increase of 24% from the previous session’s volume of 2,126,757 shares.The stock last traded at $120.2010 and had previously closed at $114.40.

Several other research firms have also recently issued reports on ABVX. BTIG Research raised their price objective on Abivax from $120.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday. Citigroup reissued a “market outperform” rating on shares of Abivax in a research note on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. Citizens Jmp raised their target price on shares of Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research report on Tuesday, December 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $142.00 target price on shares of Abivax in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $135.08.

Trending Headlines about Abivax

Here are the key news stories impacting Abivax this week:

• Positive Sentiment: M&A/takeover reports reignited buying interest — multiple outlets reported Eli Lilly interest and a potential multi‑billion euro/dollar bid, driving strong upside momentum. Article Title
• Positive Sentiment: Major business press coverage amplified the story — Wall Street Journal and Reuters reported renewed M&A chatter, increasing visibility to institutional buyers and traders. Article Title Article Title
• Positive Sentiment: Analyst/upside notes and a raised price target support optimism — at least one outlet reported a higher price target, which can validate speculative bids and attract momentum buyers. Article Title
• Neutral Sentiment: Fundamentals remain a core bullish argument — Seeking Alpha highlights obefazimod’s strong ulcerative colitis data and multiple 2026 clinical/regulatory catalysts (Phase 3 topline, potential filing paths) that make Abivax an M&A target independent of rumor. Article Title
• Neutral Sentiment: Some analyst coverage/notes provide broader context but no clear directional change — a roundup piece discusses analyst views; interpret as background rather than a fresh catalyst. Article Title
• Neutral Sentiment: Data feed anomaly on short‑interest reporting — one entry shows 0 shares (NaN change), which appears to be an error and should be treated cautiously by traders. (internal data entry)
• Negative Sentiment: Official denial from French authorities tempers takeover certainty — France’s finance ministry said it has received no request for investment approval and no contact with Eli Lilly, which may reduce the probability or timing of any deal. Article Title
• Negative Sentiment: Analyst earnings revisions are mixed/negative — Lifesci Capital cut earnings estimates, which could be used by skeptics to argue the stock is overvalued absent a deal. Article Title
• Negative Sentiment: Elevated short interest from late December (≈2.9M shares, ~3.7% of float) signals significant bearish positioning that could add selling pressure or fuel short‑squeeze dynamics when headlines move. (internal data)

Institutional Trading of Abivax

A number of institutional investors and hedge funds have recently bought and sold shares of ABVX. EverSource Wealth Advisors LLC raised its holdings in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after buying an additional 369 shares during the period. First Horizon Corp acquired a new stake in shares of Abivax in the third quarter worth $36,000. Union Bancaire Privee UBP SA acquired a new stake in shares of Abivax in the fourth quarter worth $67,000. Hantz Financial Services Inc. purchased a new position in shares of Abivax in the 3rd quarter valued at $52,000. Finally, Gordian Capital Singapore Pte Ltd acquired a new position in shares of Abivax during the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Abivax Trading Up 3.1%

The stock has a market capitalization of $9.20 billion, a PE ratio of -28.23 and a beta of 0.68. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The business’s 50-day moving average is $120.55 and its two-hundred day moving average is $86.42.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The business had revenue of ($4.92) million during the quarter. On average, analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.